Analysis | NSAID users (%) | OR (95% CI) | P value | ||
---|---|---|---|---|---|
Cases | Controls | ||||
Global (n = 152)a | NSAIDs and aspirin | 27 | 28 | 0.93 (0.52 to 1.64) | 0.79 |
NSAIDs | 24 | 21 | 1.18 (0.64 to 2.19) | 0.56 | |
Chronic treatment | 4 | 5 | 0.86 (0.24 to 2.98) | 0.78 | |
Acute treatment | 20 | 16 | 1.40 (0.69 to 2.92) | 0.32 | |
Aspirin | 5 | 10 | 0.47 (0.16 to 1.22) | 0.09 | |
Subgroup analysis | Diabetes (n = 20)a | ||||
NSAIDs | 20 | 5 | 4.00 (0.40 to 196.99) | 0.18 | |
Aspirin | 10 | 5 | 2.00 (0.40 to 196.99) | 0.56 | |
No diabetes (n = 132)a | |||||
NSAIDs | 24 | 23 | 1.05 (0.55 to 2.00) | 0.88 | |
Aspirin | 4 | 11 | 0.36 (0.10 to 1.05) | 0.04b | |
Site of infection: lung (n = 71)a | |||||
NSAIDs | 14 | 15 | 0.90 (0.32 to 2.46) | 0.82 | |
Aspirin | 7 | 11 | 0.63 (0.16 to 2.17) | 0.40 | |
Site of infection: urinary tract (n = 30)a | |||||
NSAIDs | 27 | 30 | 0.83 (0.02 to 3.28) | 0.76 | |
Aspirin | 3 | 7 | 0.50 (0.01 to 9.60) | 0.56 | |
Site of infection: skin and soft tissue (n = 16)a | |||||
NSAIDs | 31 | 31 | 1.00 (0.07 to 13.80) | 1.00 | |
Aspirin | 0 | 6 | - - | - | |
Site of infection: other (n = 35)a | |||||
NSAIDs | 37 | 20 | 2.50 (0.72 to 10.92) | 0.11 | |
Aspirin | 3 | 11 | 0.25 (0.01 to 2.53) | 0.18 |